Juno’s leukemia drug may get speedier FDA review

Post navigation

← Juno Therapeutics files for IPO, a year after founding, seeking $150M for cancer breakthroughs Juno Therapeutics raises $265 million in IPO, closes high →

Comments are closed.

Home
Contact

About Us

Grants

Startup Investments
- Investing in Washington
- Active Portfolio & Exits
In Memoriam: David J. Galas, Ph.D. (1944-2023)

News
- Articles
- Videos
- Stories

LinkedIn
Twitter

Washington Research Foundation values diversity. We’re committed to diversity, equity and inclusion in our staff, our board of directors, and the researchers, entrepreneurs and organizations we fund. We encourage people of color, women and other underserved communities to apply for our employment, grant-making and investment opportunities.

Terms of Use
Privacy Policy
(206) 336-5600
Site by The Medium

About Us
Grants
Startup Investments
- Investing in Washington
- Active Portfolio & Exits
Stories
News
- Articles
- Videos
- Reports
Contact